The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study
Status:
RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Evaluate the safety and efficacy of Pyrotinib in the transition from low-dose to normal-dose regimen for HER2-positive advanced first-line breast cancer
Phase:
PHASE2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Collaborators:
Affiliated Hospital of Jiangnan University Affiliated Hospital of Jiangsu University Affiliated Hospital of Nantong University Anhui Provincial Cancer Hospital Huai'an First People's Hospital Jingjiang People's Hospital Suzhou Municipal Hospital The Affiliated Hospital of Xuzhou Medical University The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Yancheng First People's Hospital Zhongda Hospital